Total revenues rose to around $6.07 billion, with earnings per share standing at $8.58, marking a three-fold increase from the year-ago period when the company just started ramping up its vaccine sales.
Total revenues rose to around $6.07 billion, with earnings per share standing at $8.58, marking a three-fold increase from the year-ago period when the company just started ramping up its vaccine sales.
Share this Article
Recommended